Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Abbott Reported Earlier It Will Acquire Cardiovascular Systems For $20/Share

Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
byCharles Gross
February 8, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Abbott (NYSE:ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. Under terms of the agreement, CSI stockholders will receive $20 per common share at a total expected equity value of approximately $890 million.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology And Recombinant Collagen III Platform; Co. To Pay FibroGen $8M Up Front And Up To $64M In Milestones As Well As $46M In Commercial Milestones

By Bill Haddad
Today, 6:33 AM
Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea Biosynthetic

FGEN